Sumitomo Pharma's DX

DX ScopeAreas Taken on by Sumitomo Pharma's DX

Sumitomo Pharma is a global pharmaceutical and healthcare solutions company that aims to realize the betterment of healthcare and fuller lives of people worldwide. We continuously take on challenges for seamless solutions.
We will further accelerate our DX efforts by leveraging our healthcare technology platforms and the associated talents, which we acquired through our strategic alliance with Roivant Sciences in December 2019. Through the utilization of digital technology, we will also foster a culture of innovation throughout the Sumitomo Pharma Group.

Sumitomo Pharma's DX/01

Taking on the Challenge of Creating Innovative Pharmaceuticals with DX

READ MORE

Sumitomo Pharma's DX/02

Taking on the Challenge of Creating Caring Healthcare Solutions through DX

READ MORE

Sumitomo Pharma's DX/03

Accelerating DX

READ MORE

Pick Up

Sumitomo Pharma Selected as One of the Ministry of Economy,
Trade and Industry's Noteworthy DX Companies 2021

Sumitomo Pharma was selected as one of the "Noteworthy DX Companies" in June 2021 for the second consecutive year.
This is in recognition of our wide-ranging DX initiatives, including the integration of not only IT and digital but also our group companies and each department, the creation of a DX promotion system that raises the level of digital literacy and mindset of the entire company,
the development of digital workplaces, and the company's efforts in data-driven drug discovery research and digital therapeutics (DTx)
using in silico drug discovery technology.
From 2020, the Ministry of Economy, Trade and Industry (METI) selects as "Digital Transformation (DX) Stocks" companies that are working on "Digital Transformation (DX)", which is a drastic change in business models, etc., based on digital technology,
and will lead to new growth and enhanced competitiveness.
In addition, companies that are implementing noteworthy initiatives from the perspective of expanding the scope of DX are selected as "Noteworthy DX Companies," which are second to "DX Stocks."

Reference: Ministry of Economy, Trade and Industry website (in Japanese only)
https://www.meti.go.jp/press/2021/06/20210607003/20210607003.html

Sumitovant Meeting

In March 2021, we held a meeting on the business of Sumitovant, a subsidiary of the Company,
for securities analysts, institutional investors, and the media.
Dan Rothman, Chief Information Officer of Sumitovant and Chief Digital Officer of the Sumitomo Pharma Group,
discusses digital transformation (DX).

* Sumitovant promotes the use of healthcare technology platforms in the Sumitomo Pharma Group.

READ MORE